ClinicalTrials.gg
CompletedNCT02044367Updated May 20, 2015Results posted

Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers

A Phase 1 interventional study of Dabigatran etexilate and Dabigatran etexilate in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-20.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

To investigate the relative bioavailability of dabigatran etexilate as pellets on food and of dabigatran etexilate as granules resolved in reconstitution solution, each with dabigatran etexilate as capsule following oral administration. To evaluate acceptability and palatability of Pellets sprinkled on food and Oral Liquid Formulation

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males according to the investigator's assessment, as based on the following criteria: a complete medical history including a physical examination, vital signs (Blood Pressure, Pulse Rate), 12-lead , and clinical laboratory tests
  2. Age 18 to 55 years (incl.)
  3. 18.5 to 29.9 kg/m2 (incl.)
  4. Signed and dated written prior to admission to the study in accordance with GCP and local legislation

Exclusion criteria

Exclusion criteria:

  1. Any finding in the medical examination (including Blood Pressure, Pulse Rate or ) deviating from normal and judged by the investigator.
  2. Repeated measurement of systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg
  3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  4. Any evidence of a concomitant disease judged clinically relevant by the investigator
  5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  6. Surgery of the gastrointestinal tract that could interfere with kinetics of the study drug
  7. Diseases of the central nervous system (such as epilepsy), other neurological disorders or psychiatric disorders
  8. Subjects who in the investigator's judgement are perceived as having an increased risk of bleeding, for example because of:

    • Hemorrhagic disorders or bleeding diathesis
    • Occult blood in faeces or haematuria
    • Trauma or surgery within the last month or as long as an excessive risk of bleeding persists after these events, or planned surgery during trial participation
    • History of arteriovenous malformation or aneurysm
    • History of gastroduodenal ulcer disease or gastrointestinal haemorrhage
    • History of intracranial, intraocular, spinal, retroperitoneal, or atraumatic intraarticular bleeding
    • Anemia at screening
    • Thrombocytopenia ( count less than 100/nL)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Test 1 (Treatment A)

    multiple dose of dabigatran

    Drug: Dabigatran etexilate

  • Experimental
    Test 2 (Treatment B)

    multiple dose of dabigatran

    Drug: Dabigatran etexilate

  • Experimental
    Reference

    multiple dose of dabigatran

    Drug: Dabigatran etexilate

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran.

    Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t for total dabigatran.

    Time frame: 47:55, 48:30, 49:00, 49:30, 50:00, 50:30, 51:00, 51:30, 52:00, 54:00, 56:00, 58:00, 60:00 relative to first drug administration

  2. Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran.

    Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t for total dabigatran.

    Time frame: 47:55, 48:30, 49:00, 49:30, 50:00, 50:30, 51:00, 51:30, 52:00, 54:00, 56:00, 58:00, 60:00 relative to first drug administration

Secondary outcomes

  1. Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran.

    Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t for free dabigatran.

    Time frame: 47:55, 48:30, 49:00, 49:30, 50:00, 50:30, 51:00, 51:30, 52:00, 54:00, 56:00, 58:00, 60:00 relative to first drug administration

  2. Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran.

    Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t for free dabigatran.

    Time frame: 47:55, 48:30, 49:00, 49:30, 50:00, 50:30, 51:00, 51:30, 52:00, 54:00, 56:00, 58:00, 60:00 relative to first drug administration

  3. Acceptability Rating for Pellets (on Food) and Oral Solution Will be Assessed by Asking the Subjects 1 Multiple Choice Verbal Question.

    Acceptability question: "Would you accept to take this medication for chronic use?" with 3 possible answers: Yes - No - I am not sure.

    Time frame: once on day 3 (48 hours after first dose)

  4. Palatability Rating for Pellets (on Food) and Oral Solution Will be Assessed by Asking the Subjects 1 Multiple Choice Verbal Question.

    Palatability question: "How do you rank the taste?" with 5 possible answers: Very good - Good - Fair - Acceptable - Not acceptable.

    Time frame: once on day 3 (48 hours after first dose)

07

Results

Posted Apr 27, 2015

Participant flow

Participant flow — Overall Study
MilestoneT1-T2-RT1-R-T2T2-T1-RT2-R-T1R-T1-T2R-T2-T1
Started999999
Completed999999
Not completed000000

Outcome measures

PrimaryArea Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran.

Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t for total dabigatran.

Time frame:
47:55, 48:30, 49:00, 49:30, 50:00, 50:30, 51:00, 51:30, 52:00, 54:00, 56:00, 58:00, 60:00 relative to first drug administration
Reported as:
Geometric mean · ng∙h/mL
Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran.
ng∙h/mLT1 (Treatment A)T2 (Treatment B)R (Reference)
Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran.1220 ± 34.11160 ± 27.0893 ± 46.8
Statistical analysis
  • T1 (Treatment A) vs R (Reference) · Gmean ratio t1/r (%): 137.01 · 90% CI 125.773 to 149.250The standard deviation is actually the intra-individual geometric coefficient of variation (gCV).
  • T2 (Treatment B) vs R (Reference) · Gmean ratio t2/r (%): 130.43 · 90% CI 119.628 to 142.200The standard deviation is actually the intra-individual geometric coefficient of variation (gCV).
PrimaryMaximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran.

Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t for total dabigatran.

Time frame:
47:55, 48:30, 49:00, 49:30, 50:00, 50:30, 51:00, 51:30, 52:00, 54:00, 56:00, 58:00, 60:00 relative to first drug administration
Reported as:
Geometric mean · ng/mL
Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran.
ng/mLT1 (Treatment A)T2 (Treatment B)R (Reference)
Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran.191 ± 37.4184 ± 27.3131 ± 50.8
Statistical analysis
  • T1 (Treatment A) vs R (Reference) · Gmean ratio t1/r (%): 146.16 · 90% CI 132.217 to 161.576The standard deviation is actually the intra-individual geometric coefficient of variation (gCV).
  • T2 (Treatment B) vs R (Reference) · Gmean ratio t2/r (%): 141.06 · 90% CI 127.644 to 155.876The standard deviation is actually the intra-individual geometric coefficient of variation (gCV).
SecondaryArea Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran.

Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t for free dabigatran.

Time frame:
47:55, 48:30, 49:00, 49:30, 50:00, 50:30, 51:00, 51:30, 52:00, 54:00, 56:00, 58:00, 60:00 relative to first drug administration
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran.
ng*h/mLT1 (Treatment A)T2 (Treatment B)R (Reference)
Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran.1000 ± 35.8958 ± 27.6727 ± 50.8
Statistical analysis
  • T1 (Treatment A) vs R (Reference) · Gmean ratio t1/r (%): 137.61 · 90% CI 126.418 to 149.797The standard deviation is actually the intra-individual geometric coefficient of variation (gCV).
  • T2 (Treatment B) vs R (Reference) · Gmean ratio t2/r (%): 132.00 · 90% CI 120.714 to 144.342The standard deviation is actually the intra-individual geometric coefficient of variation (gCV).
SecondaryMaximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran.

Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t for free dabigatran.

Time frame:
47:55, 48:30, 49:00, 49:30, 50:00, 50:30, 51:00, 51:30, 52:00, 54:00, 56:00, 58:00, 60:00 relative to first drug administration
Reported as:
Geometric mean · ng/mL
Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran.
ng/mLT1 (Treatment A)T2 (Treatment B)R (Reference)
Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran.157 ± 37.9154 ± 27.6106 ± 55.1
Statistical analysis
  • T1 (Treatment A) vs R (Reference) · Gmean ratio t1/r (%): 147.80 · 90% CI 133.384 to 163.779The standard deviation is actually the intra-individual geometric coefficient of variation (gCV).
  • T2 (Treatment B) vs R (Reference) · Gmean ratio t2/r (%): 144.80 · 90% CI 130.853 to 160.242The standard deviation is actually the intra-individual geometric coefficient of variation (gCV).
SecondaryAcceptability Rating for Pellets (on Food) and Oral Solution Will be Assessed by Asking the Subjects 1 Multiple Choice Verbal Question.

Acceptability question: "Would you accept to take this medication for chronic use?" with 3 possible answers: Yes - No - I am not sure.

Time frame:
once on day 3 (48 hours after first dose)
Reported as:
Number · participants
Acceptability Rating for Pellets (on Food) and Oral Solution Will be Assessed by Asking the Subjects 1 Multiple Choice Verbal Question.
participantsT1 (Treatment A)T2 (Treatment B)
Yes3729
No917
I am not sure77
SecondaryPalatability Rating for Pellets (on Food) and Oral Solution Will be Assessed by Asking the Subjects 1 Multiple Choice Verbal Question.

Palatability question: "How do you rank the taste?" with 5 possible answers: Very good - Good - Fair - Acceptable - Not acceptable.

Time frame:
once on day 3 (48 hours after first dose)
Reported as:
Number · participants
Palatability Rating for Pellets (on Food) and Oral Solution Will be Assessed by Asking the Subjects 1 Multiple Choice Verbal Question.
participantsT1 (Treatment A)T2 (Treatment B)
Very good20
Good2015
Fair1817
Acceptable1114
Not acceptable27

Adverse events

Collected over First dose of study drug date/time until the end-of-trial examination (last per protocol visit). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T1 (Treatment A)—0/54 (0%)2/54 (3.7%)
T2 (Treatment B)—0/54 (0%)3/54 (5.6%)
R (Reference)—0/54 (0%)1/54 (1.9%)
Most frequent other events
Most frequent other events
EventT1 (Treatment A)T2 (Treatment B)R (Reference)
HeadacheNervous system disorders2/543/541/54

Baseline characteristics

The evaluation of demographic and baseline characteristics were performed on the treated set which included all subjects who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Overall
Mean36.2 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female0
Male54
08

Study locations

1 site
  • 1160.194.1 Boehringer Ingelheim Investigational Site
    Biberach, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2014
First posted
Jan 24, 2014
Start
Jan 2014
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Apr 27, 2015
Last update
May 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02044367
Responsible party
Sponsor
First posted
Jan 24, 2014
Start date
Jan 2014
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Apr 27, 2015
Last update
May 20, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion